About Vaccinex

Vaccinex is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, and other targeted biological therapies. A Vaccinex antibody product is currently in clinical trials for immunotherapy of cancer and for remyelination and repair of damage to the nervous system in multiple sclerosis.

Learn More 

Clinical Trials

VX15/2503 Phase I Clinical Trial in Adult Patients with Solid Tumors

Learn More  

 

VX15/2503 Phase I Clinical Trial in Adult Patients with Multiple Sclerosis

Learn More 

Innovative Antibodies

Oncology VX15
VX35
Multiple Sclerosis VX15
AutoImmune Disease VX5

Novel Antibodies to
Clinically Validated Targets

Oncology BVX20
VX70
Inflammatory Disease VX30

NKT Vaccine Platform

Oncology and Infectious Disease VX25
Inflammatory Disease VX45

Technology Platform

Vaccinex has developed one of only a handful of major, commercial platforms for human antibody discovery. Our core technology provides for robust expression of full length IgG in mammalian cells and, when coupled with high-throughput selection, allows for the rapid identification of fully human monoclonal antibodies.

Learn More